BCR and chronic myelogenous leukemia, BCR-ABL1 positive: However, CML patients may become relatively resistant to TKI therapy, including the second generation TKIs (12,13) and, thus, the development of a therapeutic strategy that targets abnormal signaling cascades other than BCR/ABL is urgently required for CML treatment.